ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1051

Hoxd Genes Regulate Arthritis-Relevant Pathways

Kerstin Klein1, Mojca Frank Bertoncelj1, Monika Krošel1, Matija Tomšič2, Christoph Kolling3, Oliver Distler4 and Caroline Ospelt1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, 3Upper Extremity Dept., Schulthess Clinic Zurich, Zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Arthritis, Fibroblasts, hand disorders and synovium

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis and Joint Biology – Basic Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Gene expression and functions of synovial fibroblasts (SF) differ profoundly between distinct joints. This might lead to site-specific activation of arthritis-relevant pathways with implications for arthritis pathogenesis and drug targeting 1. Homeobox (HOX) transcription factors guide the proper morphogenesis of limb structural elements and appear to influence site-specific development of various diseases. Here we analyzed the expression and epigenetic regulation of HOXD genes in SF from different joints of the hand and identified their target genes and functional effects.

Methods:

The expression of HOXD in SF was analyzed by RNA sequencing (n=21), quantitative Real-time PCR (qPCR; n=14) and Western blotting (n=10). The histone marks H3K4me1 (enhancers), H3K4me3 (promoters), H3K27me3 (repressed chromatin) and H3K27ac (active chromatin) were analyzed by Chromatin Immunoprecipitation DNA sequencing (ChIPseq) in SF from one RA (finger II) and one osteoarthritis (OA; thumb) patient. HOXD10, HOXD11 and HOXD13 were silenced using antisense LNA™ GapmeRs in finger II-IV SF (n=4). The expression of potential target genes was analyzed by qPCR in joints of the hand (n=7). Growth of transfected SF (n=3) was analyzed using an impedance-based system (xCELLigence).

Results:

Among the genes in the HOX cluster, HOXD10, HOXD11 and HOXD13 transcripts and proteins were significantly increased in SF in digits II-IV (MCP, PIP) and wrists compared to SF from the thumb (CM I, MP I). This signature was independent of disease and recapitulated the embryonic HOXD expression pattern in the developing hand. ChIPseq showed an increase of H3K27ac and H3K4me3 marks in the genomic region between HOXD9 and HOXD13 in SF from an RA finger II compared to SF from an OA thumb. This was paralleled by a loss of the repressive histone mark H3K27me3 in this region in RA finger II. Similar to the low expression of HOXD10-13 in thumbs, the expression of thrombospondin 2 (THBS2; p<0.05), receptor tyrosine kinase like orphan receptor 2 (ROR2; p<0.05), collagen type XI alpha 1 chain (COL11A1; p<0.01) and ATP binding cassette subfamily C member 9 (ABCC9; p<0.05) was decreased in joints of the thumb compared to joints of digits II-IV as measured by RNAseq and qPCR. Accordingly, silencing of HOXD13 decreased the expression of THBS2 (p<0.001), ROR2 (p<0.001) and COL11A1 (p<0.01), whereas ABCC9 (p<0.01) was decreased by silencing of HOXD10 (p<0.01) and HOXD13 (p<0.01). Silencing of HOXD13 but not HOXD10 and HOXD11 reduced the proliferation of SF by 83,7% (p<0.01).

Conclusion:

HOXD10-13 exhibit an epigenetically regulated, increased expression in fingers II-IV compared to thumb that determines the site-specific signature of downstream target genes and the proliferative capacity of SF. This might influence the differential activation of arthritis-relevant pathways and patterns of OA and RA in the small joints of the fingers II-IV versus the thumb.

References: 1Frank-Bertoncelj et al., Nat Commun, 2017.


Disclosure: K. Klein, None; M. Frank Bertoncelj, None; M. Krošel, None; M. Tomšič, None; C. Kolling, None; O. Distler, Actelion, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Roche, 2,Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espeRare foundations, Genentech/Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sinoxa, UCB, 5,mir-29 for the treatment of systemic sclerosis licensed, 9; C. Ospelt, None.

To cite this abstract in AMA style:

Klein K, Frank Bertoncelj M, Krošel M, Tomšič M, Kolling C, Distler O, Ospelt C. Hoxd Genes Regulate Arthritis-Relevant Pathways [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/hoxd-genes-regulate-arthritis-relevant-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hoxd-genes-regulate-arthritis-relevant-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology